Evidence map›Paper›PMID 25320312›Full record

ArticleJournal of virology2015

Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon.

Darryll A Barkhouse, Samantha A Garcia, Emily K Bongiorno, Aurore Lebrun, Milosz Faber, D Craig Hooper

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Interferons in Systemic Lupus Erythematosus.Rheumatic diseases clinics of North America · 2021
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Darryll A BarkhouseDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Center for Neurovirology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Samantha A GarciaDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Center for Neurovirology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Emily K BongiornoDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Center for Neurovirology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Aurore LebrunDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Center for Neurovirology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Milosz FaberDepartment of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
D Craig HooperDepartment of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Center for Neurovirology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA douglas.hooper@jefferson.edu.
Thomas Jefferson University · USNeurological Surgery · US

Funding

Virus Clearance from the Central Nervous SystemR01AI093369 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI FU, ZHEN F, HOOPER, DOUGLAS CRAIG · 2011 to 2015
$4.7M
A novel single dose vaccine for pre-and post-exposure prophylaxis of rabiesR01AI093666 · NIAID · THOMAS JEFFERSON UNIVERSITY · PI FABER, MILOSZ ANDRZEJ · 2011 to 2015
$1.9M
NIAID NIH HHS R01 AI093369NIAID NIH HHS R01AI093369NIAID NIH HHS R01 AI093666NIAID NIH HHS R01AI093666NIAID NIH HHS U01AI083045
6 · The paper itself

Abstract

unlabelledPrevious animal model experiments have shown a correlation between interferon gamma (IFN-γ) expression and both survival from infection with attenuated rabies virus (RABV) and reduction of neurological sequelae. Therefore, we hypothesized that rapid production of murine IFN-γ by the rabies virus itself would induce a more robust antiviral response than would occur naturally in mice. To test this hypothesis, we used reverse engineering to clone the mouse IFN-γ gene into a pathogenic rabies virus backbone, SPBN, to produce the recombinant rabies virus designated SPBNγ. Morbidity and mortality were monitored in mice infected intranasally with SPBNγ or SPBN(-) control virus to determine the degree of attenuation caused by the expression of IFN-γ. Incorporation of IFN-γ into the rabies virus genome highly attenuated the virus. SPBNγ has a 50% lethal dose (LD50) more than 100-fold greater than SPBN(-). In vitro and in vivo mouse experiments show that SPBNγ infection enhances the production of type I interferons. Furthermore, knockout mice lacking the ability to signal through the type I interferon receptor (IFNAR(-/-)) cannot control the SPBNγ infection and rapidly die. These data suggest that IFN-γ production has antiviral effects in rabies, largely due to the induction of type I interferons. IMPORTANCE: Survival from rabies is dependent upon the early control of virus replication and spread. Once the virus reaches the central nervous system (CNS), this becomes highly problematic. Studies of CNS immunity to RABV have shown that control of replication begins at the onset of T cell entry and IFN-γ production in the CNS prior to the appearance of virus-neutralizing antibodies. Moreover, antibody-deficient mice are able to control but not clear attenuated RABV from the CNS. We find here that IFN-γ triggers the early production of type I interferons with the expected antiviral effects. We also show that engineering a lethal rabies virus to express IFN-γ directly in the infected tissue reduces rabies virus replication and spread, limiting its pathogenicity in normal and immunocompromised mice. Therefore, vector delivery of IFN-γ to the brain may have the potential to treat individuals who would otherwise succumb to infection with rabies virus.

Indexed as

AnimalsDisease Models, AnimalFemaleInterferon-gammaInterferon Type IMiceMice, KnockoutRabiesRabies virusRecombinant ProteinsSurvival AnalysisInterferon-gammaInterferon Type IRecombinant Proteins

Identifiers

PMID25320312
PMCPMC4301114
OpenAlexW2146432219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.